"Treatment-resistant" doesn't mean person-resistant
The clinical label describes what medicines have failed to do, not what a person is. That distinction changes how we read the research — and how we treat the people in it.
"Treatment-resistant depression" is one of the most consequential phrases in psychiatry, and one of the most misread. In research it usually means something quite specific: a person has completed at least two adequate courses of antidepressant treatment, at a proper dose and for a proper length of time, without enough improvement. It is a description of what has been tried. It is not a verdict on the person, and the grammar matters.
A description of medicines, not of patients
The resistance lives in the relationship between an illness and the tools currently available for it — not in some quality of the patient. People who carry the label have usually done everything asked of them, often for years. Participants in the recent Phase 3 psilocybin trials, for example, had been in their current depressive episode for more than three years on average and had lived through more than six episodes over their lives. Hearing "resistant" as a personal failing is both inaccurate and, clinically, harmful: it adds shame to an illness that already manufactures it.
The honest version of the term is: "we have not yet found the thing that helps you." That sentence keeps the door open.
Why this is the population in the trials
Much psychedelic research recruits exactly these patients, for two reasons. One is ethical: it is easier to justify an experimental treatment with unusual risks for people whose standard options have run out. The other is practical: regulators are more willing to consider a new drug for a condition where nothing else has worked.
That should shape how the results are read. In the largest Phase 2 study, about a third of people who received the higher dose met the definition of response at three weeks, and about a fifth were still responding at twelve weeks. In the Phase 3 trials that followed, the average benefit over comparison groups was a few points on a depression scale. For a group with this history, that is meaningful. It is also early, partial, and not the same as a cure. A treatment can be a real improvement on "nothing left to try" while still helping a minority of the people who receive it.
What it asks of clinicians
- Treat the label as a prompt to keep looking, not a place to stop.
- Be honest about uncertainty without communicating hopelessness.
- Remember that the person has likely heard "resistant" as "difficult" — and correct that, explicitly.
The people these studies are built around are not hard cases. They are people for whom the usual map ran out, who are still walking anyway.
Sources and further reading
- Gaynes BN et al. "Defining treatment-resistant depression." Depression and Anxiety, 2020.
- Goodwin GM et al. "Single-dose psilocybin for a treatment-resistant episode of major depression." New England Journal of Medicine, 2022.
- Compass Pathways, COMP005 and COMP006 Phase 3 announcements, 2025–2026.
This essay is general information, not medical advice.